LBIO Lion Biotechnologies Inc

Robbins Arroyo LLP: Lion Biotechnologies, Inc. (LBIO) Misled Shareholders According to a Recently Filed Class Action

Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Lion Biotechnologies, Inc. (NasdaqGM: LBIO) in the U.S. District Court for the Northern District of California. The complaint is brought on behalf of all purchasers of Lion securities between November 14, 2013 and April 10, 2017, for alleged violations of the Securities Exchange Act of 1934 by Lion's officers and directors. Lion, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells.

View this information on the law firm's Shareholder Rights Blog: www.robbinsarroyo.com/shareholders-rights-blog/lion-biotechnologies-inc

Lion Accused of Engaging in Illegal Stock Promotion Scheme

According to the complaint, Lion attested in its public filings to the accuracy of financial reporting, the disclosure of any material changes to the company's internal controls over financial reporting, and the disclosure of all fraud. On May 14, 2014, Lion stated in its 1Q 2014 Form 10-Q that it received a subpoena from the U.S. Securities and Exchange Commission ("SEC") seeking information concerning "documents and communications related to individuals who post or have posted articles regarding the Company on equity research or other financial websites." On April 10, 2017, the SEC found that Lion, through its former Chief Executive Officer Manish Singh ("Singh") engaged in a scheme to mislead investors by commissioning over ten internet publications and 20 widely distributed emails promoting Lion to potential investors that purported to be independent from the company, when, in fact, they were paid promotions. Further, Singh engaged a stock promotion firm to pay writers to publish articles about Lion on investment websites as well as to coordinate the distribution of articles to thousands of electronic mailboxes.

Lion Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Leonid Kandinov at (800) 350-6003, [email protected], or via the shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.

Attorney Advertising. Past results do not guarantee a similar outcome.

EN
11/05/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lion Biotechnologies Inc

 PRESS RELEASE

Iovance Announces Positive Results from the First Clinical Trial for T...

Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas 50% Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced positive early data from a led by ...

 PRESS RELEASE

Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year...

Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates ~30% Quarterly Revenue Growth Driven by Amtagvi Demand Gross Margin Increased to 50% FY25 Revenue of $264M Achieved Annual Guidance U.S. FDA Fast Track Designation Granted for Lifileucel in Second-Line Advanced Non-Small Cell Lung Cancer SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating ...

 PRESS RELEASE

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing...

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SAN CARLOS, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on February 19, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 3,600 shares of Iovance’s common stock to two new, non-executive ...

 PRESS RELEASE

Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Fi...

Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026 SAN CARLOS, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast on Tuesday, February 24, 2026 at 8:30 a.m. ET to report its fourth quarter and full year 2025 financial results and corporate updates. To list...

 PRESS RELEASE

Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Adva...

Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma 52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control Rate SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced data demonstrating a best-in-class profile for commercial Amtagvi® (lifileucel) with unprecedented response rates in a ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch